FGFR4 and cancer: FGFR4 overexpression increased Bcl-x expression at the mRNA and protein level through the MAPK cascade, implying that FGFR4 inhibitors (e.g., opposing antibodies) combined with chemotherapeutic drugs should be used for treating FGFR4-overexpressing cancers (Roidl et al., 2009).